ImmunoGen Reports Recent Progress and 2Q 2023 Financial Results. In Other News, Anna Berkenblit, MD, Senior VP and CMO Stepping Down from Her Position

ImmunoGen in the News
WALTHAM, Mass.--(BUSINESS WIRE) --Jul. 31, 2023-- ImmunoGen (IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today reviewed recent progress in the business and reported financial results for the quarter ended June 30, 2023.
From ImmunoGen
Mark Enyedy, ImmunoGen’s President and Chief Executive Officer said, “This quarter we achieved a . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.